Stage IIIA squamous lung cancer with pathologic complete response after immunochemotherapy

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: PD-L1 TPS 90%; PD-L1 CPS 100%; EGFR p.G719S 24.9%; EGFR p.S768I 24.6%; TP53 p.S183* 7.2%; TMB 0.0 Muts/Mb

Systematic imaging in March 2025 showed no recurrence or metastasis, with postoperative disease-free survival longer than 30 months and overall survival longer than 34 months.

PubMed CentralRead more →

Stage IV Large-Cell Neuroendocrine Lung Cancer Controlled for Nearly Four Years With Multiple Treatments

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: PD-L1 high initially; no actionable driver mutation; later PD-L1 5%

Metastatic Site: liver, bones

After several partial responses across multiple treatment lines, she entered hospice and died on December 13, 2024, after an overall survival of 47 months.

PubMed CentralRead more →

Stage IVA lung adenosquamous carcinoma: complete response after paclitaxel, nedaplatin, and tislelizumab

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Adenosquamous lung cancer markers; PD-L1 TPS 18%; KRAS, BRAF, PIK3CA, FLT1 mutation; TMB 3.7

Metastatic Site: pleura/chest wall, cervical lymph nodes, axillary…

As of March 30, 2025, he maintained complete response with normal tumor markers, no radiologic evidence of progression or recurrence, and progression-free survival of 46.5 months after paclitaxel/nedaplatin/tislelizumab followed by maintenance tislelizumab.

PubMed CentralRead more →

Aggressive Lung Squamous Cell Carcinoma With Tumor Extension Into the Heart

Patient Info: Anonymized, male, 50s

Biomarkers: PD-L1 high

The cancer progressed rapidly despite treatment, and he died 3 months after diagnosis and 2 months after starting chemotherapy and pembrolizumab.

PubMed CentralRead more →

Stage I Pleomorphic Lung Cancer Recurring With Bone Metastasis Within Five Months

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 high; no detected driver mutation

Metastatic Site: bone

PET-CT in December 2024 showed a partial response. As of February 2025, he remained on sintilimab and bevacizumab maintenance with about 9 months of progression-free survival after recurrence treatment.

PubMed CentralRead more →

Stage IV Lung Adenocarcinoma With KRAS Mutation Responding to Immunotherapy and Anti-Angiogenic Treatment

Patient Info: Anonymized, male | Stage IV

Biomarkers: KRAS mutation; MET amplification

Metastatic Site: pleura

By the December 2023 follow-up, the pleural effusion had disappeared, the primary lung tumor had not progressed, and he was described as symptom-free and in good health on maintenance treatment.

PubMed CentralRead more →

MSI-H locally advanced right colon cancer: pathologic complete response after oxaliplatin, capecitabine, and immunotherapy

Patient Info: Anonymized, Female, 60s

Biomarkers: MSI-H on tumor gene testing

After oxaliplatin, capecitabine, and sindilizumab conversion therapy followed by laparoscopic radical right hemicolectomy, postoperative pathology showed no viable tumor cells and tumor regression grade 0 complete response.

PubMed CentralRead more →

Lung Cancer Responds to Chemo-Immunotherapy Despite a Benign Liver Pseudotumor

Patient Info: Anonymized, male, 60s

After immunotherapy was stopped, follow-up scans continued to show a partial response in the lung cancer, and he remained clinically stable at the latest follow-up.

PubMed CentralRead more →

Stage IV ALK Non-Small Cell Lung Cancer: Alisa's Patient Story

Patient Info: Alisa Secaida, Female, Under 40 | Stage IV

Biomarkers: ALK-positive / ALK-rearranged

Metastatic Site: Brain; lymph nodes

As of May 2025, after alectinib and lung surgery, pathology still showed active tumor and lymph-node cancer cells, and Alisa was receiving IMRT for remaining disease.

City of HopeRead more →

Poorly Differentiated Lung Adenocarcinoma Recurring After Surgery and Chemotherapy

Patient Info: Anonymized, male, 60s

Biomarkers: No driver mutation identified initially; recurrent tumor PD-L1 >50%

The cancer recurred in June 2024 with a para-aortic mass and enlarged mediastinal and supraclavicular lymph nodes. Camrelizumab was started, but he could not tolerate it and declined further treatment.

PubMed CentralRead more →

Stage IV Colorectal Cancer: Esteban's Survivor Story

Patient Info: Esteban Moreno | Stage IV

Biomarkers: Lynch syndrome

After immunotherapy and surgery for Stage IV colorectal cancer, Esteban reported recent scans showing no signs of cancer and described himself as NED.

Fight Colorectal CancerRead more →

NRG1-Fusion Lung Adenocarcinoma With a Partial Response to Afatinib

Patient Info: Anonymized, female, 50s

Biomarkers: CD74-NRG1 fusion

Afatinib produced a partial response lasting 24 weeks, with progression after 32 weeks on treatment. She died in April 2022.

PubMed CentralRead more →

HER2-Positive Breast Cancer With Brain and Leptomeningeal Metastases Responding to Intrathecal Treatment

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: brain, leptomeninges

More than 5 years after her September 2019 diagnosis, neurological symptoms had resolved, cerebrospinal fluid remained negative for tumor cells, and maintenance treatment was continuing in February 2025.

PubMed CentralRead more →

Stage IV Lung Adenocarcinoma Presenting as Persistent Chest Pain and Rib Metastasis

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: TP53 mutation; PD-L1 30%; no sensitive driver mutation identified

Metastatic Site: bone

After delayed diagnosis of Stage IV lung adenocarcinoma with a painful rib metastasis, he began systemic immunotherapy and local treatment for the painful bone lesion.

PubMed CentralRead more →

Lynch syndrome bifocal colon cancer: complete pathological remission after sintilimab

Patient Info: Anonymized, Male, 40s | Stage III

Biomarkers: Lynch-associated colon cancer with MSI-H and KRAS/NRAS/BRAF wild type; tumor markers were low or near normal.

As of April 2025, pathology after proximal colectomy showed tumor regression grade 0 with complete pathological remission, and follow-up found no recurrence or metastasis.

PubMed CentralRead more →

Metastatic SMARCA4-Deficient Lung Cancer Controlled for More Than Two Years With Tislelizumab and Fruquintinib

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: PD-L1 8%; no target-sensitive mutation identified

Metastatic Site: left adrenal gland, cervical lymph nodes

After radiotherapy reduced the cervical-node metastasis, imaging on April 26, 2024 showed stable disease. He ended trial treatment after 2 years and continued regular follow-up.

PubMed CentralRead more →

Metastatic lung squamous cell carcinoma: no recurrence after chemoimmunotherapy and pembrolizumab maintenance

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion; PD-L1 TPS 95%; TTF-1-negative; p40-positive

Metastatic Site: mediastinal lymph nodes; bilateral lung nodules

As of April 2025, PET/CT 3 years after treatment initiation showed no sign of recurrence after carboplatin, nab-paclitaxel, pembrolizumab, and 2 years of pembrolizumab monotherapy.

PubMed CentralRead more →

Stage IV squamous lung cancer: partial response complicated by pulmonary artery pseudoaneurysm

Patient Info: Anonymized, Male, 60s | Stage IV

Metastatic Site: distant sites not specified (M1c1)

As of April 2025, tumor imaging showed partial remission/significant reduction, and the pulmonary artery pseudoaneurysm was successfully embolized with no recurrent hemoptysis over 6 months.

PubMed CentralRead more →

Early-stage mixed breast carcinoma found during LGI1 limbic encephalitis workup

Patient Info: Anonymized, Female | Stage I

Biomarkers: ER 95-100% positive; PR 80% positive; HER2-negative

She gradually recovered after immunotherapy for limbic encephalitis and excision of the early-stage breast tumor, and had returned to part-time work 12 months after discharge.

PubMed CentralRead more →

Lung inflammation from pembrolizumab immunotherapy returned months after stopping treatment

Patient Info: Anonymized, Female, 70+

Biomarkers: Estrogen receptor-negative; progesterone receptor-negative; HER2-negative

Surgery confirmed a pathologic complete response, and she remained in breast-cancer remission during routine follow-up after treatment for recurrent pembrolizumab-related pneumonitis.

PubMed CentralRead more →

Small-Cell Lung Cancer With Later Brain and Other Metastases in a Woman With COPD

Patient Info: Anonymized, female, 50s | Stage IV

Metastatic Site: central nervous system

Her neurologic condition progressively worsened after immune-related encephalitis and extensive metastatic progression. She died from sepsis 8 months after the lung-cancer diagnosis.

PubMed CentralRead more →

Metastatic lung adenocarcinoma: pembrolizumab response complicated by pulmonary arterial hypertension

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: CK7-positive; TTF-1-positive; p40 focally positive; high tumor mutational burden; no targetable mutations identified

Metastatic Site: right axillary lymph node; right hilar lymph nodes;…

As of April 2025, the patient was tolerating single-agent pemetrexed without evidence of lung cancer progression, while pulmonary arterial hypertension symptoms had improved on riociguat and macitentan.

PubMed CentralRead more →

Metastatic Neuroendocrine Breast Cancer With Severe Hormone Overproduction

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER-negative, PR focally positive, HER2-negative, PIK3CA mutation

Metastatic Site: liver, bone

Died after rapid deterioration and cardiac arrest during progressive metastatic disease.

PubMed CentralRead more →

Stage 4 SMARCA4-deficient lung cancer: ongoing treatment response

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: SMARCA4-deficient lung cancer with BRG-1 loss, CK/CK7 positive, Ki-67 >40%. CEA

Metastatic Site: sigmoid colon, left adrenal gland

After colon metastasis surgery, continued radiotherapy, and later gemcitabine/nedaplatin/bevacizumab/camrelizumab for adrenal metastasis, the cancer showed a favorable response with no further recurrence or new metastasis reported.

PubMed CentralRead more →